NUDT15中间代谢者应以较低6-TGN目标水平调整硫唑嘌呤剂量以避免白细胞减少
该回顾性观察研究纳入167例接受硫唑嘌呤治疗的韩国儿童炎症性肠病患者,发现NUDT15中间代谢者白细胞减少发生率高于正常代谢者,且6-TGN水平与白细胞减少正相关;作者建议NUDT15中间代谢者以较低的6-TGN目标水平(<167.1 pmol/8×10^8红细胞)调整硫唑嘌呤剂量。
要点
- NUDT15中间代谢者白细胞减少发生率高于正常代谢者(44% vs 16%,P<0.001)。
- NUDT15中间/TPMT正常代谢者中,白细胞减少组6-TGN中位数361.3 vs 无白细胞减少组263.8 pmol/8×10^8红细胞(P=0.013)。
- 作者建议NUDT15中间代谢者以6-TGN<167.1 pmol/8×10^8红细胞为目标调整硫唑嘌呤剂量。
核心结论
- NUDT15多态性与韩国儿童炎症性肠病患者硫唑嘌呤治疗期间白细胞减少的发生时间相关。
- 为将NUDT15中间代谢者硫嘌呤诱导的白细胞减少发生率降至<15%,作者建议以较低的6-TGN目标水平(<167.1 pmol/8×10^8红细胞)调整硫唑嘌呤剂量。
研究设计与样本
- 回顾性观察研究,纳入接受硫唑嘌呤治疗并接受NUDT15和TPMT基因分型的韩国儿童炎症性肠病患者167例。
- 通过定期硫嘌呤代谢物监测调整硫唑嘌呤剂量,分析白细胞减少发生时间相关因素及NUDT15多态性与6-TGN水平的关系。
主要发现
- NUDT15正常代谢者白细胞减少发生率为16%(19/119),中间代谢者为44%(20/45),慢代谢者为100%(3/3),P<0.001。
- NUDT15多态性与白细胞减少发生时间显著相关(HR=5.26,95%CI=2.74-10.09,P<0.001)。
- NUDT15中间/TPMT正常代谢者中,6-TGN水平与白细胞减少呈正相关(中位数361.3 vs 263.8 pmol/8×10^8红细胞,P=0.013)。
关键数值与推荐
- NUDT15中间/TPMT正常代谢者中,与白细胞减少相关的最准确6-TGN截断值为308.2 pmol/8×10^8红细胞(AUC=0.742,95%CI=0.569-0.915,灵敏度80.0%,特异度72.7%,P<0.001)。
- 当特异度设定为<15%时,6-TGN截断值为167.1 pmol/8×10^8红细胞(灵敏度93.3%,特异度13.6%)。
临床怎么用
- 作者建议NUDT15中间代谢者以6-TGN<167.1 pmol/8×10^8红细胞为目标水平调整硫唑嘌呤剂量,以将白细胞减少发生率控制在<15%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between NUDT15 polymorphisms and thiopurine-induced leucopenia is well known. AIM: To investigate the association between NUDT15 polymorphisms and time-to-leucopenia in paediatric patients with inflammatory bowel disease (IBD) receiving azathioprine and to determine the relationship between NUDT15 polymorphisms and 6-thioguanine nucleotide (6-TGN) levels. METHODS: This retrospective observational study included Korean paediatric patients with IBD who were treated with azathioprine and underwent NUDT15 and TPMT genotyping. Azathioprine doses were adjusted by regular thiopurine metabolite monitoring. Factors associated with time-to-leucopenia and the relationship between NUDT15 polymorphisms and 6-TGN levels were analysed. RESULTS: Among the 167 patients included, leucopenia was observed in 16% (19/119), 44% (20/45) and 100% (3/3) of the NUDT15 normal, intermediate and poor metabolisers respectively (P < 0.001). NUDT15 polymorphism was significantly associated with time-to-leucopenia (HR = 5.26, 95% CI = 2.74-10.09, P < 0.001). There was a positive association between 6-TGN levels and leucopenia among the NUDT15 intermediate/TPMT normal metabolisers (median 361.3 vs 263.8 pmol/8 × 108 RBC, P = 0.013). The most accurate 6-TGN cut-off level associated with leucopenia was 308.2 pmol/8 × 108 RBC (AUC = 0.742, 95% CI = 0.569-0.915, sensitivity 80.0%, specificity 72.7%, P < 0.001) in this subgroup. When the specificity was set to <15%, the 6-TGN cut-off level was 167.1 pmol/8 × 108 RBC (sensitivity 93.3%, specificity 13.6%). CONCLUSIONS: NUDT15 polymorphisms were associated with time-to-leucopenia during azathioprine treatment in Korean paediatric patients with IBD. In order to reduce the development of thiopurine-induced leucopenia (<15%) in NUDT15 intermediate metabolisers, adjustment of azathioprine doses should be based on a lower 6-TGN target level (<167.1 pmol/8 × 108 RBC).
引用
- Kang B, Kim TJ, Choi J, et al. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers. Aliment Pharmacol Ther. 2020. PMID: 32598049. doi:10.1111/apt.15810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。